ReviewJournal of clinical hypertension (Greenwich, Conn.)2005
Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Calcium channel blockers for people with chronic kidney disease requiring dialysis.The Cochrane database of systematic reviews · 2020Pooled it
- Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis.BMC medicine · 2012Pooled it
- Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers.European journal of drug metabolism and pharmacokineticsTrial
- Validation of the hepatic blood flow rate model for verapamil first-pass metabolism.European journal of drug metabolism and pharmacokineticsTrial
- Pharmacokinetic Variability of Direct Oral Anticoagulants and Calcium Channel Blockers: A Comparative Analysis of Exposure Data from Clinical Studies.Pharmaceutics · 2026Article
- Rationale for a New Low-Dose Triple Single Pill Combination for the Treatment of Hypertension.Global heart · 2024Article
- Rhabdomyolysis in a Long-Term Statin User Without Traditional Risk Factors: A Case Report.Cureus · 2023Article
- Epidemiology and management of antiretroviral-associated cardiovascular disease.The open AIDS journal · 2015Article
- Drug interactions and antiretroviral drug monitoring.Current HIV/AIDS reports · 2014Review
- Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.Biochimica et biophysica acta · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcium channel blockers (CCBs) comprise a heterogeneous group of compounds with unique structures and pharmacologic characteristics. These agents are employed in the treatment of hypertension, coronary ischemia, and/or supraventricular arrhythmias. CCBs are both substrates for, and in the instance of verapamil and diltiazem inhibitors of, cytochrome P450 3A4. In the case of verapamil and diltiazem, this inhibitory effect increases the likelihood of drug-drug interactions with other compounds similarly metabolized by cytochrome P450 3A4. Much of the debate with reference to a cardiovascular risk for CCBs has been quieted with the advent of sustained-release delivery systems that offer a more gradual rate of drug delivery. The most common side effects with CCBs are vasodilatory in nature and include peripheral edema, flushing, and headache. Despite the potential for side effects with CCBs, their potent blood pressure-lowering effect makes them a prerequisite for blood pressure control in many patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.